DENOSUMAB: A NEW ERA IN OSTEOPOROSIS MANAGEMENT IN VIETNAM

Nguyen Van Tuan 1, 2 , , Ho Pham Thuc Lan 3, 4
1 UNSW Sydney image/svg+xml
2 University of Technology Sydney image/svg+xml
3 Trường Đại học Y khoa Phạm Ngọc Thạch image/svg+xml
4 Saigonmec, Ho Chi Minh City, Vietnam
* Tác giả liên hệ:

Thông tin bài viết

Thống kê
Lượt tải: 200 Lượt xem: 40
DOI
10.63947/bvtn.v1i5.2
Xuất bản
01-11-2025
Số Tập 1 Số 5 (2025): Thong Nhat Hospital’s 50-Year Journey - Comprehensive Healthcare and Healthy Aging
Chuyên mục
Báo cáo tổng quan
Danh mục
Nghiên cứu khoa học

Tải bài viết

PDF (Tiếng Anh)

Cách trích dẫn

1.
Van Tuan N, Pham Thuc Lan H. DENOSUMAB: A NEW ERA IN OSTEOPOROSIS MANAGEMENT IN VIETNAM. JHA [Internet]. Vietnam; 2025 tháng 11 1 [cited 2025 tháng 11 5];1(5):4–10. https://tcsuckhoelaohoa.vn/bvtn/article/view/129 doi: 10.63947/bvtn.v1i5.2
Đang tải trích dẫn...
Crossref
Scopus
Google Scholar
Europe PMC

Tóm tắt

Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased fracture risk. In Vietnam, the disease affects ~30% in postmenopausal women and ~10% in men over 50, highlighting a growing public health challenge as the population ages. Bisphosphonates remain the standard firstline treatment. Recent advances in bone biology highlight the critical role of the RANK/RANKL/OPG pathway in bone remodeling. Osteoporosis arises when the RANKL/OPG ratio becomes imbalanced. Denosumab, a monoclonal antibody that targets RANKL, replicates OPG’s ability to suppress osteoclast activity, increasing bone mineral density and reducing fracture risk by 20–68% across various skeletal sites. Unlike bisphosphonates, Denosumab is reversible, metabolized by the reticuloendothelial system, and appropriate for patients with advanced kidney disease, though it necessitates monitoring for hypocalcemia. This advancement offers clinicians a valuable tool for managing osteoporosis in Vietnam.

 

Từ khóa

osteoporosis denosumab RANKL/OPG

Tài liệu tham khảo

  1. National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. URL: http://www.nof.org/professionals/NOF_Clinicians_Guide.pdf . Accessed: 08 July 2008. 2008.
  2. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353(9156):878-82. DOI: https://doi.org/10.1016/S0140-6736(98)09075-8
  3. Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152(6):380-90. DOI: https://doi.org/10.7326/0003-4819-152-6-201003160-00008
  4. Pongchaiyakul C, Nguyen ND, Jones G, Center JR, Eisman JA, Nguyen TV. Asymptomatic vertebral deformity as a major risk factor for subsequent fractures and mortality: a long-term prospective study. J Bone Miner Res. 2005;20(8):1349-55. DOI: https://doi.org/10.1359/JBMR.050317
  5. Nguyen ND, Ahlborg HG, Center JR, Eisman JA, Nguyen TV. Residual lifetime risk of fractures in women and men. J Bone Miner Res. 2007;22(6):781-8. DOI: https://doi.org/10.1359/jbmr.070315
  6. Blume SW, Curtis JR. Medical costs of osteoporosis in the elderly Medicare population. Osteoporos Int. 2011;22(6):1835-44. DOI: https://doi.org/10.1007/s00198-010-1419-7
  7. Ho-Pham LT, Nguyen TV. The Vietnam Osteoporosis Study: Rationale and design. Osteoporosis and Sarcopenia. 2017;2:90-7. DOI: https://doi.org/10.1016/j.afos.2017.06.001
  8. Ho-Pham LT, Nguyen UD, Pham HN, Nguyen ND, Nguyen TV. Reference ranges for bone mineral density and prevalence of osteoporosis in Vietnamese men and women. BMC Musculoskelet Disord. 2011;12:182. DOI: https://doi.org/10.1186/1471-2474-12-182
  9. Hoang DK, Doan MC, Mai LD, Ho-Le TP, Ho-Pham LT. Burden of osteoporosis in Vietnam: An analysis of population risk. PLoS One. 2021;16(6):e0252592. DOI: https://doi.org/10.1371/journal.pone.0252592
  10. Ho-Pham LT, Nguyen ND, Vu BQ, Pham HN, Nguyen TV. Prevalence and risk factors of radiographic vertebral fracture in postmenopausal Vietnamese women. Bone. 2009;45(2):213-7. DOI: https://doi.org/10.1016/j.bone.2009.04.199
  11. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535-41. DOI: https://doi.org/10.1016/S0140-6736(96)07088-2
  12. Nguyen ND, Eisman JA, Nguyen TV. Anti-Hip Fracture Efficacy of Bisphosphonates: A Bayesian Analysis of Clinical Trials. J Bone Miner Res. 2006;21(1):340-9. DOI: https://doi.org/10.1359/JBMR.050903
  13. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005;353(6):555-65. DOI: https://doi.org/10.1056/NEJMoa050336
  14. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis research & therapy. 2007;9 Suppl 1:S1. DOI: https://doi.org/10.1186/ar2165
  15. Blair JM, Zhou H, Seibel MJ, Dunstan CR. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol. 2006;3(1):41-9. DOI: https://doi.org/10.1038/ncponc0381
  16. Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009;24(2):182-95. DOI: https://doi.org/10.1359/jbmr.081112
  17. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756- 65. DOI: https://doi.org/10.1056/NEJMoa0809493
  18. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-23. DOI: https://doi.org/10.1016/S2213-8587(17)30138-9
  19. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153-61. DOI: https://doi.org/10.1359/jbmr.0809010
  20. Kendler D, Chines A, Clark P, Ebeling PR, McClung M, Rhee Y, et al. Bone Mineral Density After Transitioning From Denosumab to Alendronate. J Clin Endocrinol Metab. 2020;105(3):e255-64. DOI: https://doi.org/10.1210/clinem/dgz095
  21. Ban JK, Hao BB, McCarthy L, Guilcher SJT, Cadarette SM. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap. Osteoporos Int. 2019;30(9):1865-72. DOI: https://doi.org/10.1007/s00198-019-05051-1
  22. Hadji P, Papaioannou N, Gielen E, Feudjo Tepie M, Zhang E, Frieling I, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015;26(10):2479-89. DOI: https://doi.org/10.1007/s00198-015-3164-4
  23. Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, et al. Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99(7):2599-607. DOI: https://doi.org/10.1210/jc.2013-4175
  24. Rhee Y, Chang DG, Ha J, Kim S, Lee Y, Jo E, et al. Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea. Endocrinol Metab (Seoul). 2022;37(3):497-505. DOI: https://doi.org/10.3803/EnM.2022.1427

Giấy phép

© 2025 Tác giả. Xuất bản bởi Tạp chí Sức khỏe và Lão hóa.

Creative Commons License

Tác phẩm này được cấp phép theo Giấy phép Creative Commons Ghi công-Phi thương mại-Không phái sinh 4.0 Quốc tế.